Trade Names:Dayhist-1- Tablets 1.34 mg as fumarate (equiv. to 1 mg clemastine)
Trade Names:Tavist Allergy- Tablets 1.34 mg as fumarate (equiv. to 1 mg clemastine)
Trade Names:Clemastine Fumarate- Tablets 2.68 mg (equiv. to 2 mg clemastine)- Syrup 0.67 mg per 5 mL (equiv. to 0.5 mg clemastine)
Competitively antagonizes histamine at H 1 receptor sites.
Well absorbed. T max is 2 to 5 h.
Excreted in breast milk.
Metabolized in the liver by mono- and didemethylation and glucuronide conjugation.
Excreted mainly via urine.
5 to 7 h.
10 to 12 h, possibly up to 24 h.
Relief of symptoms associated with allergic rhinitis or other upper respiratory allergies, such as sneezing, rhinorrhea, pruritus, and lacrimation; relief of mild, uncomplicated allergic skin manifestation of urticaria and angioedema.
Hypersensitivity to antihistamines; MAOI therapy; use in newborn or premature infants and in nursing women.
PO 1.34 mg every 12 h (max 2.68 mg every 24 h).Children younger than 12 yr of age
Consult a doctor.SyrupAdults and children 12 years of age and older
PO 1.34 mg bid.Children 6 to 12 yr of age
PO 0.67 to 1.34 mg bid.
Store 1.34 mg tablets at controlled room temperature (59° to 86°F). Store 2.68 mg tablets and oral syrup below 77°F.
May cause additive CNS depressant effects.MAOIs
May increase anticholinergic effects of clemastine fumarate.
Drug may prevent or diminish otherwise positive reaction to dermal reactivity indicators.
Orthostatic hypotension; palpitations; bradycardia; tachycardia; arrhythmias.
Acute labyrinthitis; confusion; convulsions; disturbed coordination; dizziness; euphoria; excitation; fatigue; hysteria; insomnia; irritability; nervousness; neuritis; paresthesias; restlessness; sedation; sleepiness; tremor; vertigo.
Blurred vision; tinnitus; diplopia.
Epigastric distress; nausea; vomiting; diarrhea; constipation.
Urinary frequency; difficult urination; urinary retention; early menses.
Hemolytic anemia; thrombocytopenia; agranulocytosis.
Increased appetite; weight gain.
Thickening of bronchial secretions; chest tightness; wheezing; nasal stuffiness; dry mouth, nose and throat; sore throat; respiratory depression.
Hypersensitivity reactions; photosensitivity.
Assess allergy symptoms (eg, cough, rhinitis, nasal congestion, sneezing, watery eyes, itching nose, throat, or eyes) before starting therapy and periodically during therapy. Notify health care provider if symptoms are not improving or are getting worse.Dizziness/Drowsiness
Monitor patient for dizziness and excessive drowsiness. If noted, hold therapy and notify health care provider.Review therapy
Ensure that therapy is periodically reviewed to determine if therapy needs to be continued without change or if a dose change (eg, increase, decrease, discontinuation) is indicated.
Contraindicated in nursing mothers.
Safety and efficacy not established in children under 12 yr of age.Syrup
Safety and efficacy not established in children under 6 yr of age.
Elderly and debilitated patients are at an increased risk of dizziness, excessive sedation, syncope, toxic confusional states, and hypotension. Dosage reduction may be required.
Use drug with caution in patients predisposed to urinary retention, history of bronchial asthma, increased IOP, hyperthyroidism, CV disease, or hypertension. Avoid use in patients with history of sleep apnea. Use with considerable caution in patients with narrow-angle glaucoma, stenosing peptic ulcer, pyloroduodenal obstruction, symptomatic prostatic hypertrophy, or bladder neck obstruction.
CNS depression or stimulation, hallucinations, convulsions, CV collapse, dry mouth, fixed dilated pupils, flushing.
Copyright © 2009 Wolters Kluwer Health.